{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:16Z","timestamp":1792784836663,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315459"],"award-info":[{"award-number":["315459"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315460"],"award-info":[{"award-number":["315460"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UEF Doctoral Programme in Molecular Medicine (DPMM); ALS tutkimuksen tuki ry."},{"name":"Esko Laukala and Eeva Kehus-Laukala fund"},{"name":"UEF Doctoral Programme in Molecular Medicine (DPMM)and GenomMed"},{"DOI":"10.13039\/501100007083","name":"Orionin Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Frontotemporal lobar degeneration (FTLD) comprises a heterogenous group of fatal neurodegenerative diseases and, to date, no validated diagnostic or prognostic biomarkers or effective disease-modifying therapies exist for the different clinical or genetic subtypes of FTLD. Current treatment strategies rely on the off-label use of medications for symptomatic treatment. Changes in several neurotransmitter systems including the glutamatergic, GABAergic, dopaminergic, and serotonergic systems have been reported in FTLD spectrum disease patients. Many FTLD-related clinical and neuropsychiatric symptoms such as aggressive and compulsive behaviour, agitation, as well as altered eating habits and hyperorality can be explained by disturbances in these neurotransmitter systems, suggesting that their targeting might possibly offer new therapeutic options for treating patients with FTLD. This review summarizes the present knowledge on neurotransmitter system deficits and synaptic dysfunction in model systems and patients harbouring the most common genetic causes of FTLD, the hexanucleotide repeat expansion in\n                    <jats:italic>C9orf72<\/jats:italic>\n                    and mutations in the granulin (\n                    <jats:italic>GRN)<\/jats:italic>\n                    and microtubule-associated protein tau\n                    <jats:italic>(MAPT)<\/jats:italic>\n                    genes. We also describe the current pharmacological treatment options for FLTD that target different neurotransmitter systems.\n                  <\/jats:p>","DOI":"10.1038\/s41380-021-01384-8","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T06:02:53Z","timestamp":1637301773000},"page":"1300-1309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration\u2014Insights into disease mechanisms and current therapeutic approaches"],"prefix":"10.1038","volume":"27","author":[{"given":"Nadine","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Korhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Leskel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-0850","authenticated-orcid":false,"given":"Hannah","family":"Rostalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paavo","family":"Honkakoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-9524","authenticated-orcid":false,"given":"Eino","family":"Solje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-2957","authenticated-orcid":false,"given":"Annakaisa","family":"Haapasalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"1384_CR1","first-page":"2456","volume":"143","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. A J Neurol. 2011;143:2456\u201377.","journal-title":"A J Neurol"},{"key":"1384_CR2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\u201314.","journal-title":"Neurology."},{"key":"1384_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11940-014-0319-0","volume":"16","author":"RM Tsai","year":"2014","unstructured":"Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014;16:1\u201314.","journal-title":"Curr Treat Options Neurol"},{"key":"1384_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12031-011-9632-1","volume":"45","author":"AJ Espay","year":"2011","unstructured":"Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia: the clinical overlap. J Mol Neurosci. 2011;45:343\u20139. NIH Public Access.","journal-title":"J Mol Neurosci"},{"key":"1384_CR5","doi-asserted-by":"publisher","first-page":"1780.e13","DOI":"10.1016\/j.neurobiolaging.2014.01.149","volume":"35","author":"E Solje","year":"2014","unstructured":"Solje E, Hartikainen P, Valori M, Vanninen R, Tiihonen J, Hakola P, et al. The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation. Neurobiol Aging. 2014;35:1780.e13\u20131780.e17.","journal-title":"Neurobiol Aging"},{"key":"1384_CR6","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","volume":"386","author":"J Bang","year":"2015","unstructured":"Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672\u201382.","journal-title":"Lancet."},{"key":"1384_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","volume":"129","author":"DJ Irwin","year":"2015","unstructured":"Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129:469\u201391.","journal-title":"Acta Neuropathol"},{"key":"1384_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","volume":"11","author":"E Majounie","year":"2012","unstructured":"Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323\u201330.","journal-title":"Lancet Neurol"},{"key":"1384_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE, Majounie E, Waite A, Sim\u00f3n-S\u00e1nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257\u201368.","journal-title":"Neuron."},{"key":"1384_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron. 2011;72:245\u201356.","journal-title":"Neuron."},{"key":"1384_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt231","volume":"6","author":"ME Murray","year":"2014","unstructured":"Murray ME, Kouri N, Lin WL, Jack CR, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimer\u2019s Res Ther. 2014;6:1.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1384_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB. Neurotransmitter deficits from fronto temporal lobar degeneration. Brain 2018;141:1263\u201385.","journal-title":"Brain"},{"issue":"Suppl 1","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jnc.13622","volume":"138","author":"C Pottier","year":"2016","unstructured":"Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem.2016;138 Suppl 1:32\u201353.","journal-title":"J Neurochem."},{"key":"1384_CR14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266:2075\u201386.","journal-title":"J Neurol."},{"key":"1384_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s40142-014-0063-5","volume":"3","author":"A Haapasalo","year":"2015","unstructured":"Haapasalo A, Remes AM. Genetic and molecular aspects of frontotemporal lobar degeneration. Curr Genet Med Rep. 2015;3:8\u201318.","journal-title":"Curr Genet Med Rep."},{"key":"1384_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000351859","volume":"3","author":"A-L Kaivorinne","year":"2013","unstructured":"Kaivorinne A-L, Bode MK, Paavola L, Tuominen H, Kallio M, Renton AE, et al. Clinical characteristics of C9ORF72-linked frontotemporal lobar degeneration. Dement Geriatr Cogn Dis Extra. 2013;3:251\u201362.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"1384_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1126\/science.1232927","volume":"339","author":"K Mori","year":"2013","unstructured":"Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS. Science (80-). 2013;339:1335\u20138.","journal-title":"Science (80-)"},{"key":"1384_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00401-013-1192-8","volume":"126","author":"TF Gendron","year":"2013","unstructured":"Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PEA, Caulfield T, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD\/ALS. Acta Neuropathol. 2013;126:829\u201344.","journal-title":"Acta Neuropathol"},{"key":"1384_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40478-018-0579-0","volume":"6","author":"P Frick","year":"2018","unstructured":"Frick P, Sellier C, Mackenzie IRA, Cheng CY, Tahraoui-Bories J, Martinat C, et al. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun. 2018;6:72.","journal-title":"Acta Neuropathol Commun"},{"key":"1384_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-013-1147-0","volume":"126","author":"P Fratta","year":"2013","unstructured":"Fratta P, Poulter M, Lashley T, Rohrer JD, Polke JM, Beck J, et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol. 2013;126:401\u20139.","journal-title":"Acta Neuropathol"},{"key":"1384_CR21","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.aaf1064","volume":"351","author":"JG O\u2019Rourke","year":"2016","unstructured":"O\u2019Rourke JG, Bogdanik L, Y\u00e1\u00f1ez A, Lall D, Wolf AJ, Muhammad AKMG, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science (80-). 2016;351:1324\u20139.","journal-title":"Science (80-)"},{"key":"1384_CR22","doi-asserted-by":"publisher","first-page":"23204","DOI":"10.1038\/srep23204","volume":"6","author":"A Atanasio","year":"2016","unstructured":"Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;6:23204.","journal-title":"Sci Rep."},{"key":"1384_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/ana.24453","volume":"78","author":"M Koppers","year":"2015","unstructured":"Koppers M, Blokhuis AM, Westeneng HJ, Terpstra ML, Zundel CAC, Vieira De S\u00e1 R, et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol. 2015;78:426\u201338.","journal-title":"Ann Neurol"},{"key":"1384_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.4490","volume":"24","author":"Y Shi","year":"2018","unstructured":"Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS\/FTD human induced motor neurons. Nat Med. 2018;24:313\u201325.","journal-title":"Nat Med"},{"key":"1384_CR25","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.15252\/embj.201593350","volume":"35","author":"C Sellier","year":"2016","unstructured":"Sellier C, Campanari M, Julie Corbier C, Gaucherot A, Kolb\u2010Cheynel I, Oulad\u2010Abdelghani M, et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin\u20102 to induce motor neuron dysfunction and cell death. EMBO J 2016;35:1276\u201397.","journal-title":"EMBO J"},{"key":"1384_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainres.2018.02.011","volume":"1693","author":"A Starr","year":"2018","unstructured":"Starr A, Sattler R. Synaptic dysfunction and altered excitability in C9ORF72 ALS\/FTD. Brain Res. 2018;1693:98\u2013108.","journal-title":"Brain Res"},{"key":"1384_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tibs.2012.11.001","volume":"38","author":"A Iacoangeli","year":"2013","unstructured":"Iacoangeli A, Tiedge H. Translational control at the synapse: role of RNA regulators. Trends Biochem Sci. 2013;38:47\u201355.","journal-title":"Trends Biochem Sci"},{"key":"1384_CR28","doi-asserted-by":"publisher","first-page":"e08881","DOI":"10.7554\/eLife.08881","volume":"4","author":"AS Burguete","year":"2015","unstructured":"Burguete AS, Almeida S, Gao F-B, Kalb R, Akins MR, Bonini NM GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife. 2015;4:e08881","journal-title":"Elife."},{"key":"1384_CR29","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1093\/hmg\/ddx304","volume":"26","author":"S Perry","year":"2017","unstructured":"Perry S, Han Y, Das A, Dickman D. Homeostatic plasticity can be induced and expressed to restore synaptic strength at neuromuscular junctions undergoing ALS-related degeneration. Hum Mol Genet. 2017;26:4153\u201367.","journal-title":"Hum Mol Genet"},{"key":"1384_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00401-014-1329-4","volume":"128","author":"S May","year":"2014","unstructured":"May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, et al. C9orf72 FTLD\/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128:485\u2013503.","journal-title":"Acta Neuropathol"},{"key":"1384_CR31","doi-asserted-by":"publisher","first-page":"e10722","DOI":"10.15252\/emmm.201910722","volume":"12","author":"BK Jensen","year":"2020","unstructured":"Jensen BK, Schuldi MH, McAvoy K, Russell KA, Boehringer A, Curran BM, et al. Synaptic dysfunction induced by glycine\u2010alanine dipeptides in C9orf72\u2010 ALS \/ FTD is rescued by SV 2 replenishment. EMBO Mol Med. 2020;12:e10722","journal-title":"EMBO Mol Med."},{"key":"1384_CR32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.stemcr.2020.03.023","volume":"14","author":"R Dafinca","year":"2020","unstructured":"Dafinca R, Barbagallo P, Farrimond L, Candalija A, Scaber J, Ababneh NA, et al. Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS\/FTD. Stem Cell Rep. 2020;14:892\u2013908.","journal-title":"Stem Cell Rep."},{"key":"1384_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms6999","volume":"6","author":"A-C Devlin","year":"2015","unstructured":"Devlin A-C, Burr K, Borooah S, Foster JD, Cleary EM, Geti I, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6:1\u201312.","journal-title":"Nat Commun"},{"key":"1384_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrn.2016.37","volume":"17","author":"JM Henley","year":"2016","unstructured":"Henley JM, Wilkinson KA. Synaptic AMPA receptor composition in development, plasticity and disease. Nat Rev Neurosci. 2016;17:337\u201350.","journal-title":"Nat Rev Neurosci"},{"key":"1384_CR35","doi-asserted-by":"publisher","first-page":"11917","DOI":"10.1523\/JNEUROSCI.2021-10.2010","volume":"30","author":"T Hideyama","year":"2010","unstructured":"Hideyama T, Yamashita T, Suzuki T, Tsuji S, Higuchi M, Seeburg PH, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q\/R site-unedited GluR2. J Neurosci 2010;30:11917\u201325.","journal-title":"J Neurosci"},{"key":"1384_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","volume":"80","author":"CJ Donnelly","year":"2013","unstructured":"Donnelly CJ, Zhang P-W, Pham JT, Haeusler AR, Heusler AR, Mistry NA, et al. RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80:415\u201328.","journal-title":"Neuron"},{"key":"1384_CR37","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.1523\/JNEUROSCI.0908-18.2018","volume":"38","author":"W Xu","year":"2018","unstructured":"Xu W, Xu J. C9orf72 dipeptide repeats cause selective neurodegeneration and cell-autonomous excitotoxicity in Drosophila glutamatergic neurons. J Neurosci. 2018;38:7741\u201352.","journal-title":"J Neurosci."},{"key":"1384_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-021-00433-8","volume":"16","author":"EM Perkins","year":"2021","unstructured":"Perkins EM, Burr K, Banerjee P, Mehta AR, Dando O, Selvaraj BT, et al. Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction. Mol Neurodegener. 2021;16:13.","journal-title":"Mol Neurodegener"},{"key":"1384_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/archneurol.2011.53","volume":"68","author":"AS Chen-Plotkin","year":"2011","unstructured":"Chen-Plotkin AS, Martinez-Lage M, Sleiman PMA, Hu W, Greene R, Wood EMC, et al. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol. 2011;68:488\u201397.","journal-title":"Arch Neurol"},{"key":"1384_CR40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1471-4159.2007.04968.x","volume":"104","author":"JL Eriksen","year":"2008","unstructured":"Eriksen JL, Mackenzie IRA. Progranulin: normal function and role in neurodegeneration. J Neurochem 2008;104:287\u201397.","journal-title":"J Neurochem"},{"key":"1384_CR41","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.nbd.2011.10.016","volume":"45","author":"TL Petkau","year":"2012","unstructured":"Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, et al. Synaptic dysfunction in progranulin-deficient mice. Neurobiol Dis. 2012;45:711\u201322.","journal-title":"Neurobiol Dis"},{"key":"1384_CR42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1124\/jpet.117.242164","volume":"363","author":"F Longhena","year":"2017","unstructured":"Longhena F, Zaltieri M, Grigoletto J, Faustini G, La Via L, Ghidoni R, et al. Depletion of progranulin reduces GluN2B-containing NMDA receptor density, tau phosphorylation, and dendritic arborization in mouse primary cortical neurons. J Pharm Exp Ther 2017;363:164\u201375.","journal-title":"J Pharm Exp Ther"},{"key":"1384_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40478-020-01037-x","volume":"8","author":"M Huang","year":"2020","unstructured":"Huang M, Modeste E, Dammer E, Merino P, Taylor G, Duong DM, et al. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations. Acta Neuropathol Commun. 2020;8:163.","journal-title":"Acta Neuropathol Commun"},{"key":"1384_CR44","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.cell.2016.04.001","volume":"165","author":"H Lui","year":"2016","unstructured":"Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165:921\u201335.","journal-title":"Cell."},{"key":"1384_CR45","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1523\/JNEUROSCI.6244-10.2011","volume":"31","author":"L Tapia","year":"2011","unstructured":"Tapia L, Milnerwood A, Guo A, Mills F, Yoshida E, Vasuta C, et al. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. J Neurosci. 2011;31:11126\u201332.","journal-title":"J Neurosci"},{"key":"1384_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.410410606","volume":"41","author":"NL Foster","year":"1997","unstructured":"Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D\u2019Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol.1997;41:706\u201315. John Wiley & Sons, Ltd.","journal-title":"Ann Neurol."},{"key":"1384_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1750-3639.1999.tb00550.x","volume":"9","author":"L Bu\u00e9e","year":"1999","unstructured":"Bu\u00e9e L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick\u2019s disease. Brain Pathol. 1999;9:681\u201393. International Society of Neuropathology.","journal-title":"Brain Pathol"},{"key":"1384_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45:384\u20139. NIH Public Access.","journal-title":"J Mol Neurosci"},{"key":"1384_CR49","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","volume":"84","author":"J Avila","year":"2004","unstructured":"Avila J, Lucas JJ, P\u00e9rez M, Hern\u00e1ndez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84:361\u201384.","journal-title":"Physiol Rev"},{"key":"1384_CR50","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1126\/science.1152993","volume":"319","author":"R Dixit","year":"2008","unstructured":"Dixit R, Ross JL, Goldman YE, Holzbaur ELF. Differential regulation of dynein and kinesin motor proteins by tau. Science (80-). 2008;319:1086\u20139.","journal-title":"Science (80-)"},{"key":"1384_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/ncb1528","volume":"9","author":"TA Fulga","year":"2007","unstructured":"Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2007;9:139\u201348.","journal-title":"Nat Cell Biol"},{"key":"1384_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TCC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007;53:337\u201351.","journal-title":"Neuron"},{"key":"1384_CR53","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","volume":"68","author":"BR Hoover","year":"2010","unstructured":"Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067\u201381.","journal-title":"Neuron."},{"key":"1384_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun. 2020;11:1\u201315. 111. 2020","journal-title":"Nat Commun"},{"key":"1384_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-017-0488-7","volume":"5","author":"A Mudher","year":"2017","unstructured":"Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alavi Naini SM, et al. What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun. 2017;5:1\u201320. 51. 2017","journal-title":"Acta Neuropathol Commun"},{"key":"1384_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00401-019-02075-z","volume":"139","author":"E-J Kim","year":"2020","unstructured":"Kim E-J, Hwang J-HL, Gaus SE, Nana AL, Deng J, Brown JA, et al. Evidence of corticofugal tau spreading in patients with frontotemporal dementia. Acta Neuropathol. 2020;139:27.","journal-title":"Acta Neuropathol"},{"key":"1384_CR57","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0000000000004232","volume":"89","author":"A Benussi","year":"2017","unstructured":"Benussi A, Di Lorenzo F, Dell\u2019Era V, Cosseddu M, Alberici A, Caratozzolo S, et al. Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. Neurology. 2017;89:665\u201372.","journal-title":"Neurology."},{"key":"1384_CR58","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.pbb.2011.08.008","volume":"100","author":"MJ Niciu","year":"2012","unstructured":"Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharm Biochem Behav. 2012;100:656\u201364.","journal-title":"Pharm Biochem Behav"},{"key":"1384_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2019.00304","volume":"13","author":"A Benussi","year":"2019","unstructured":"Benussi A, Alberici A, Buratti E, Ghidoni R, Gardoni F, Di Luca M, et al. Toward a glutamate hypothesis of frontotemporal dementia. Front Neurosci. 2019;13:1\u20139.","journal-title":"Front Neurosci"},{"key":"1384_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000051214","volume":"10","author":"I Ferrer","year":"1999","unstructured":"Ferrer I. Neurons and their dendrites in frontotemporal dementia. Dement Geriatr Cogn Disord. 1999;10:55\u201360.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1384_CR61","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3233\/JAD-180293","volume":"65","author":"A Padovani","year":"2018","unstructured":"Padovani A, Benussi A, Cantoni V, Dell\u2019Era V, Cotelli MS, Caratozzolo S, et al. Diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease with transcranial magnetic stimulation. J Alzheimer\u2019s Dis. 2018;65:221\u201330.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"1384_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06117-y","volume":"7","author":"B Borroni","year":"2017","unstructured":"Borroni B, Stanic J, Verpelli C, Mellone M, Bonomi E, Alberici A, et al. Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target. Sci Rep. 2017;7:1\u201310.","journal-title":"Sci Rep."},{"key":"1384_CR63","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbr.2012.01.007","volume":"229","author":"A Adamczyk","year":"2012","unstructured":"Adamczyk A, Mejias R, Takamiya K, Yocum J, Krasnova IN, Calderon J, et al. GluA3-deficiency in mice is associated with increased social and aggressive behavior and elevated dopamine in striatum. Behav Brain Res. 2012;229:265\u201372.","journal-title":"Behav Brain Res"},{"key":"1384_CR64","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11011-014-9560-1","volume":"30","author":"C Wu","year":"2015","unstructured":"Wu C, Sun D. GABA receptors in brain development, function, and injury. Metab Brain Dis. 2015;30:367\u201379.","journal-title":"Metab Brain Dis"},{"key":"1384_CR65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0149-7634(05)80177-0","volume":"16","author":"RG Paredes","year":"1992","unstructured":"Paredes RG, \u00c5gmo A. GABA and behavior: the role of receptor subtypes. Neurosci Biobehav Rev. 1992;16:145\u201370.","journal-title":"Neurosci Biobehav Rev"},{"key":"1384_CR66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10571-018-0632-3","volume":"39","author":"MO Klein","year":"2019","unstructured":"Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG. Dopamine: functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019;39:31\u201359.","journal-title":"Cell Mol Neurobiol"},{"key":"1384_CR67","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1212\/WNL.58.10.1489","volume":"58","author":"JO Rinne","year":"2002","unstructured":"Rinne JO, Laine M, Kaasinen V, Norvasuo-Heil\u00e4 MK, N\u00e5gren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58:1489\u201393.","journal-title":"Neurology."},{"key":"1384_CR68","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.parkreldis.2014.06.004","volume":"20","author":"J Siuda","year":"2014","unstructured":"Siuda J, Fujioka S, Wszolek ZK. Parkinsonian syndrome in familial frontotemporal dementia. Park Relat Disord. 2014;20:957\u201364.","journal-title":"Park Relat Disord"},{"key":"1384_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.13001","volume":"6","author":"HK Park","year":"2013","unstructured":"Park HK, Chung SJ. New perspective on parkinsonism in frontotemporal lobar degeneration. J Mov Disord. 2013;6:1\u20138.","journal-title":"J Mov Disord."},{"key":"1384_CR70","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/eat.20984","volume":"45","author":"A Broft","year":"2012","unstructured":"Broft A, Shingleton R, Kaufman J, Liu F, Kumar D, Slifstein M, et al. Striatal dopamine in bulimia nervosa: a PET imaging study. Int J Eat Disord. 2012;45:648\u201356.","journal-title":"Int J Eat Disord"},{"key":"1384_CR71","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1001\/jamaneurol.2014.1931","volume":"71","author":"RM Ahmed","year":"2014","unstructured":"Ahmed RM, Irish M, Kam J, Van Keizerswaard J, Bartley L, Samaras K, et al. Quantifying the eating abnormalities in frontotemporal dementia. JAMA Neurol. 2014;71:1540\u20136.","journal-title":"JAMA Neurol"},{"key":"1384_CR72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/157015906776359540","volume":"4","author":"L Ciranna","year":"2006","unstructured":"Ciranna L. Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol. 2006;4:101\u201314.","journal-title":"Curr Neuropharmacol"},{"key":"1384_CR73","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnins.2013.00036","volume":"7","author":"MH Donovan","year":"2013","unstructured":"Donovan MH, Tecott LH. Serotonin and the regulation of mammalian energy balance. Front Neurosci. 2013;7:36.","journal-title":"Front Neurosci"},{"key":"1384_CR74","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/aww162","volume":"139","author":"A Maillet","year":"2016","unstructured":"Maillet A, Krack P, Lhomm\u00e9e E, M\u00e9t\u00e9reau E, Klinger H, Favre E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u2019s disease. Brain. 2016;139:2486\u2013502.","journal-title":"Brain."},{"key":"1384_CR75","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-007-0992-8","volume":"196","author":"DM Bowen","year":"2008","unstructured":"Bowen DM, Procter AW, Mann DMA, Snowden JS, Esiri MM, Neary D, et al. Imbalance of a serotonergic system in frontotemporal dementia: Implication for pharmacotherapy. Psychopharmacol (Berl). 2008;196:603\u201310.","journal-title":"Psychopharmacol (Berl)"},{"key":"1384_CR76","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3233\/JAD-160320","volume":"53","author":"Y Vermeiren","year":"2016","unstructured":"Vermeiren Y, Janssens J, Aerts T, Martin JJ, Sieben A, Van Dam D, et al. Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2016;53:1079\u201396.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"1384_CR77","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s004010000293","volume":"101","author":"Y Yang","year":"2001","unstructured":"Yang Y, Schmitt HP. Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol. 2001;101:256\u201370.","journal-title":"Acta Neuropathol"},{"key":"1384_CR78","doi-asserted-by":"publisher","first-page":"R1051","DOI":"10.1016\/j.cub.2015.09.039","volume":"25","author":"LA Schwarz","year":"2015","unstructured":"Schwarz LA, Luo L. Organization of the locus coeruleus-norepinephrine system. Curr Biol. 2015;25:R1051\u2013R1056.","journal-title":"Curr Biol"},{"key":"1384_CR79","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.brainres.2016.01.005","volume":"1641","author":"B Xing","year":"2016","unstructured":"Xing B, Li YC, Gao WJ. Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex. Brain Res. 2016;1641:217\u201333.","journal-title":"Brain Res"},{"key":"1384_CR80","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fnins.2015.00220","volume":"9","author":"M Gannon","year":"2015","unstructured":"Gannon M, Che P, Chen Y, Jiao K, Roberson ED, Wang Q. Noradrenergic dysfunction in Alzheimer\u2019s disease. Front Neurosci. 2015;9:220.","journal-title":"Front Neurosci"},{"key":"1384_CR81","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1073\/pnas.1320827111","volume":"111","author":"DJ Chandler","year":"2014","unstructured":"Chandler DJ, Gao WJ, Waterhouse BD. Heterogeneous organization of the locus coeruleus projections to prefrontal and motor cortices. Proc Natl Acad Sci USA. 2014;111:6816\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1384_CR82","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","volume":"76","author":"MR Picciotto","year":"2013","unstructured":"Picciotto MR. Acetylcholine as a neuromodulator. Neuron. 2013;76:116\u201329.","journal-title":"Neuron."},{"key":"1384_CR83","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cortex.2016.07.004","volume":"83","author":"S Teipel","year":"2016","unstructured":"Teipel S, Raiser T, Riedl L, Riederer I, Schroeter ML, Bisenius S, et al. Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex. 2016;83:124\u201335.","journal-title":"Cortex."},{"key":"1384_CR84","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nicl.2016.11.027","volume":"13","author":"N Nelissen","year":"2017","unstructured":"Nelissen N, Bormans G, Vandenberghe R, Dupont P, Vandenberghe R, Vandenberghe R. Cholinergic depletion and basal forebrain volume in primary progressive aphasia. NeuroImage Clin. 2017;13:271\u20139.","journal-title":"NeuroImage Clin"},{"key":"1384_CR85","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3389\/fnins.2019.01309","volume":"13","author":"J L\u00f3pez-\u00c1lvarez","year":"2019","unstructured":"L\u00f3pez-\u00c1lvarez J, Sevilla-Llewellyn-Jones J, Ag\u00fcera-Ortiz L. Anticholinergic drugs in geriatric psychopharmacology. Front Neurosci. 2019;13:1309.","journal-title":"Front Neurosci"},{"key":"1384_CR86","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178\u201385.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1384_CR87","doi-asserted-by":"publisher","first-page":"13040","DOI":"10.1073\/pnas.0905267106","volume":"106","author":"SM Smith","year":"2009","unstructured":"Smith SM, Fox PT, Miller KL, Glahn DC, Fox PM, Mackay CE, et al. Correspondence of the brain\u2019s functional architecture during activation and rest. Proc Natl Acad Sci USA. 2009;106:13040\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1384_CR88","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/brain\/awu248","volume":"137","author":"SE Lee","year":"2014","unstructured":"Lee SE, Khazenzon AM, Trujillo AJ, Guo CC, Yokoyama JS, Sha SJ, et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain. 2014;137:3047\u201360.","journal-title":"Brain."},{"key":"1384_CR89","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1212\/WNL.0000000000000583","volume":"83","author":"EGP Dopper","year":"2014","unstructured":"Dopper EGP, Rombouts SARB, Jiskoot LC, Heijer T Den, De Graaf JRA, De Koning I, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology. 2014;83:e19\u201326.","journal-title":"Neurology"},{"key":"1384_CR90","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2009.03.024","volume":"62","author":"WW Seeley","year":"2009","unstructured":"Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42.","journal-title":"Neuron."},{"key":"1384_CR91","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.cortex.2012.09.017","volume":"49","author":"M Filippi","year":"2013","unstructured":"Filippi M, Agosta F, Scola E, Canu E, Magnani G, Marcone A, et al. Functional network connectivity in the behavioral variant of frontotemporal dementia. Cortex. 2013;49:2389\u2013401.","journal-title":"Cortex."},{"key":"1384_CR92","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.cortex.2012.09.008","volume":"49","author":"NAS Farb","year":"2013","unstructured":"Farb NAS, Grady CL, Strother S, Tang-Wai DF, Masellis M, Black S, et al. Abnormal network connectivity in frontotemporal dementia: evidence for prefrontal isolation. Cortex. 2013;49:1856\u201373.","journal-title":"Cortex."},{"key":"1384_CR93","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1212\/WNL.0b013e31822c61f2","volume":"77","author":"JL Whitwell","year":"2011","unstructured":"Whitwell JL, Josephs KA, Avula R, Tosakulwong N, Weigand SD, Senjem ML, et al. Altered functional connectivity in asymptomatic MAPT subjects A comparison to bvFTD. Neurology. 2011;77:866\u201374.","journal-title":"Neurology."},{"key":"1384_CR94","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/brain\/awq075","volume":"133","author":"J Zhou","year":"2010","unstructured":"Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer\u2019s disease. Brain. 2010;133:1352\u201367.","journal-title":"Brain."},{"key":"1384_CR95","first-page":"147","volume":"65","author":"L Sellami","year":"2018","unstructured":"Sellami L, Bocchetta M, Masellis M, Cash DM, Dick KM, Van Swieten J, et al. Distinct neuroanatomical correlates of neuropsychiatric symptoms in the three main forms of genetic frontotemporal dementia in the GENFI Cohort. J Alzheimer\u2019s Dis. 2018;65:147\u201363.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"1384_CR96","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JAD-150340","volume":"51","author":"E Premi","year":"2016","unstructured":"Premi E, Cauda F, Costa T, Diano M, Gazzina S, Gualeni V, et al. Looking for neuroimaging markers in frontotemporal lobar degeneration clinical trials: a multi-voxel pattern analysis study in granulin disease. J Alzheimer\u2019s Dis. 2016;51:249\u201362.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"1384_CR97","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425\u201331.","journal-title":"Lancet."},{"key":"1384_CR98","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl J Med. 1994;330:585\u201391.","journal-title":"N. Engl J Med."},{"key":"1384_CR99","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"PC Casarotto","year":"2021","unstructured":"Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184:1299\u2013313.e19.","journal-title":"Cell."},{"key":"1384_CR100","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17482960601073543","volume":"8","author":"JMH Anneser","year":"2007","unstructured":"Anneser JMH, Jox RJ, Borasio GD. Inappropriate sexual behaviour in a case of ALS and FTD: Successful treatment with sertraline. Amyotroph Lateral Scler. 2007;8:189\u201390.","journal-title":"Amyotroph Lateral Scler"},{"key":"1384_CR101","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/brain\/awv133","volume":"138","author":"LE Hughes","year":"2015","unstructured":"Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain. 2015;138:1961\u201375.","journal-title":"Brain."},{"key":"1384_CR102","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"JB Deakin","year":"2004","unstructured":"Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacol (Berl). 2004;172:400\u20138.","journal-title":"Psychopharmacol (Berl)"},{"key":"1384_CR103","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000077171","volume":"17","author":"F Lebert","year":"2004","unstructured":"Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: A randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1384_CR104","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/153331750201700504","volume":"17","author":"TW Chow","year":"2002","unstructured":"Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17:267\u201372.","journal-title":"Am J Alzheimers Dis Other Demen."},{"key":"1384_CR105","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4088\/JCP.v69n1219a","volume":"69","author":"ED Huey","year":"2008","unstructured":"Huey ED, Section CN, Garcia C, Grant W, Clinical M, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008;69:1981\u20132.","journal-title":"J Clin Psychiatry."},{"key":"1384_CR106","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/153331750301800410","volume":"18","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer\u2019s disease and other dementias: A 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205\u201314.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1384_CR107","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","volume":"169","author":"M Steinberg","year":"2012","unstructured":"Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concern. Am J Psychiatry. 2012;169:900\u20136.","journal-title":"Am J Psychiatry."},{"key":"1384_CR108","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/brain\/aws004","volume":"135","author":"BF Boeve","year":"2012","unstructured":"Boeve BF, Boylan KB, Graff-Radford NR, Dejesus-Hernandez M, Knopman DS, Pedraza O, et al. Characterization of frontotemporal dementia and\/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135:765\u201383.","journal-title":"Brain."},{"key":"1384_CR109","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1468-1331.2007.02035.x","volume":"15","author":"CJ Kerrsens","year":"2008","unstructured":"Kerrsens CJ, Pijnenburg YAL. Vulnerability to neuroleptic side effects in frontotemporal dementia. Eur J Neurol. 2008;15:111\u20132.","journal-title":"Eur J Neurol"},{"key":"1384_CR110","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012;53:26\u201333.","journal-title":"Epilepsia."},{"key":"1384_CR111","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/stem.2388","volume":"34","author":"R Dafinca","year":"2016","unstructured":"Dafinca R, Scaber J, Ababneh N, Lalic T, Weir G, Christian H, et al. C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal demen. Stem Cells. 2016;34:2063\u201378.","journal-title":"Stem Cells"},{"key":"1384_CR112","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/JCP.0b013e31823f91b9","volume":"32","author":"CE Poetter","year":"2012","unstructured":"Poetter CE, Stewart JT. Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. J Clin Psychopharmacol. 2012;32:137\u20138.","journal-title":"J Clin Psychopharmacol."},{"key":"1384_CR113","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4088\/PCC.v02n0304","volume":"2","author":"S Gupta","year":"2000","unstructured":"Gupta S, Ivfesand PS, Frank BL, Lockwood KL, Keller PL. Topiramate in bipolar and schizoaffective disorders: Weight loss and efficacy. Prim Care Companion J Clin Psychiatry. 2000;2:96\u2013100.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"1384_CR114","doi-asserted-by":"publisher","first-page":"JCNSD.S4365","DOI":"10.4137\/JCNSD.S4365","volume":"3","author":"GC Minton","year":"2011","unstructured":"Minton GC, Miller AD, Bookstaver PB, Love BL. Topiramate: safety and efficacy of its use in the prevention and treatment of migraine. J Cent Nerv Syst Dis. 2011;3:JCNSD.S4365.","journal-title":"J Cent Nerv Syst Dis."},{"key":"1384_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2019.00450","volume":"13","author":"F Limanaqi","year":"2019","unstructured":"Limanaqi F, Biagioni F, Ryskalin L, Busceti CL, Fornai F. Molecular mechanisms linking ALS\/FTD and psychiatric disorders, the potential effects of lithium. Front Cell Neurosci. 2019;13:1\u201310.","journal-title":"Front Cell Neurosci"},{"key":"1384_CR116","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain. 2018;141:1917\u201333.","journal-title":"Brain."},{"key":"1384_CR117","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00002512-200421140-00003","volume":"21","author":"R Moretti","year":"2004","unstructured":"Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931\u20137.","journal-title":"Drugs Aging"},{"key":"1384_CR118","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","volume":"15","author":"MF Mendez","year":"2007","unstructured":"Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings? Behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84\u201387.","journal-title":"Am J Geriatr Psychiatry."},{"key":"1384_CR119","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","volume":"53","author":"CG Parsons","year":"2007","unstructured":"Parsons CG, St\u00f6ffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2014too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699\u2013723.","journal-title":"Neuropharmacology."},{"key":"1384_CR120","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/gps.1973","volume":"23","author":"J Diehl\u2010Schmid","year":"2008","unstructured":"Diehl\u2010Schmid J, F\u00f6rstl H, Perneczky R, Pohl C, Kurz A. A 6\u2010month, open\u2010label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23:754\u20139.","journal-title":"Int J Geriatr Psychiatry."},{"key":"1384_CR121","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/WAD.0b013e318197852f","volume":"23","author":"AL Boxer","year":"2010","unstructured":"Boxer AL, Lipton AM, Womack K, Neuhaus J, Pavlic D, Gandhi A, et al. An open label study of memantine treatment in three subtypes of frontotemporal lobar degeneration. Alzheimer Disord Assoc Disord. 2010;23:211\u20137.","journal-title":"Alzheimer Disord Assoc Disord"},{"key":"1384_CR122","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","volume":"12","author":"AL Boxer","year":"2013","unstructured":"Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149\u201356.","journal-title":"Lancet Neurol"},{"key":"1384_CR123","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.npp.1300886","volume":"31","author":"S Rahman","year":"2006","unstructured":"Rahman S, Robbins TW, Hodges JR, Mehta MA, Nestor PJ, Clark L, et al. Methylphenidate (\u2018Ritalin\u2019) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651\u20138.","journal-title":"Neuropsychopharmacology."},{"key":"1384_CR124","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/gps.602","volume":"17","author":"R Moretti","year":"2002","unstructured":"Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Effects of selegiline on fronto-temporal dementia: A neuropsychological evaluation. Int J Geriatr Psychiatry. 2002;17:391\u20132.","journal-title":"Int J Geriatr Psychiatry."},{"key":"1384_CR125","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4088\/PCC.v02n0602","volume":"2","author":"PA Marken","year":"2000","unstructured":"Marken PA, Stuart, Munro J. Selecting a selective serotonin reuptake inhibitor: Clinically important distinguishing features. Prim Care Companion J Clin Psychiatry. 2000;2:205\u201310.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"1384_CR126","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.neuron.2014.07.041","volume":"83","author":"Z Su","year":"2014","unstructured":"Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD\/ALS. Neuron 2014;83:1043\u201350.","journal-title":"Neuron"},{"key":"1384_CR127","doi-asserted-by":"crossref","unstructured":"Brown DG, Shorter J, Wobst HJ Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. Bioorganic Med Chem Lett. 2020;30:126942.","DOI":"10.1016\/j.bmcl.2019.126942"},{"key":"1384_CR128","doi-asserted-by":"crossref","unstructured":"Cappella M, Ciotti C, Cohen-tannoudji M, Biferi MG Gene therapy for ALS \u2014 A perspective. Int J Mol Sci. 2019;20:4388.","DOI":"10.3390\/ijms20184388"},{"key":"1384_CR129","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/JEP.S262352","volume":"13","author":"M Giunta","year":"2021","unstructured":"Giunta M, Solje E, Gardoni F, Borroni B, Benussi A. Experimental disease-modifying agents for frontotemporal lobar degeneration. J Exp Pharmacol. 2021;13:359\u201376.","journal-title":"J Exp Pharmacol"},{"key":"1384_CR130","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/archneur.1991.00530140061018","volume":"48","author":"RC Reba","year":"1991","unstructured":"Reba RC, Gibson R, Molchan S, Sunderland T, Coppola R, Jones DW, et al. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia: a controlled study with 123iqnb and single photon emission computed tomography. Arch Neurol. 1991;48:169\u201376.","journal-title":"Arch Neurol"},{"key":"1384_CR131","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000051219","volume":"10","author":"AW Procter","year":"1999","unstructured":"Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord. 1999;10:80\u201384.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1384_CR132","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","volume":"20","author":"N Herrmann","year":"2012","unstructured":"Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, Lanct\u00f4t KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20:789\u201397.","journal-title":"Am J Geriatr Psychiatry."},{"key":"1384_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2014.03.019","volume":"7","author":"BJ Wainger","year":"2014","unstructured":"Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Steve SW, Berry JD, et al. Intrinsic membrane hyperexcitability of ALS patient-derived motor neurons. Cell Rep. 2014;7:1\u201311.","journal-title":"Cell Rep."},{"key":"1384_CR134","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1155\/2013\/547853","volume":"27","author":"C Singam","year":"2013","unstructured":"Singam C, Walterfang M, Mocellin R, Evans A, Velakoulis D. Topiramate for abnormal eating behaviour in frontotemporal dementia. Behav Neurol. 2013;27:285\u20136.","journal-title":"Behav Neurol"},{"key":"1384_CR135","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/WAD.0b013e318047df5d","volume":"21","author":"MM Swanberg","year":"2007","unstructured":"Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21:164\u20136.","journal-title":"Alzheimer Dis Assoc Disord"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01384-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01384-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01384-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T16:59:16Z","timestamp":1699808356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01384-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":135,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1038\/s41380-021-01384-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"14 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}